Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete Apr 7, 2020 Nov 17, 2020
Caprelsa Vandetanib Medullary Thyroid Cancer Reimburse with clinical criteria and/or conditions Complete Aug 15, 2016 Mar 30, 2017
Cotellic Cobimetinib Metastatic melanoma Reimburse with clinical criteria and/or conditions Complete Dec 11, 2015 Jun 30, 2016
Cyramza Ramucirumab Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma Reimburse with clinical criteria and/or conditions Complete Apr 15, 2015 Oct 29, 2015
Cyramza Ramucirumab Cancelled
Darzalex Daratumumab Rd for MM Reimburse with clinical criteria and/or conditions Complete Jul 17, 2019 Mar 5, 2020
Darzalex Daratumumab BMP for Multiple Myeloma (newly diagnosed) Reimburse with clinical criteria and/or conditions Complete Jan 4, 2019 Aug 29, 2019
Darzalex Daratumumab Multiple Myeloma (second-line) Reimburse with clinical criteria and/or conditions Complete Mar 3, 2017 Oct 5, 2017
Darzalex Daratumumab Multiple Myeloma Do not reimburse Complete Apr 21, 2016 Dec 1, 2016
Daurismo Glasdegib Acute Myeloid Leukemia (AML) Do not reimburse Complete May 6, 2020 Jan 8, 2021